
SRIW, Sowalfin, Noshaq and CCF (Centre de Cautionnement et de Financement du Valais) are now part of the AARDEX Adventure.
SRIW, Sowalfin, Noshaq and CCF (Centre de Cautionnement et de Financement du Valais) are now part of the AARDEX Adventure.
When bringing a new drug product to market, powerful motivating forces are involved. And while the potential for enhancing, or even extending, the lives of patients unquestionably takes primacy, there is another inescapably influential factor in the mix: profitability. For
The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside